The company expects Q4 and FY18 net sales of GOCOVRI to be ~$13.3M and ~$34M, respectively.
The Company reported preliminary total prescriptions of ~5,700 for Q4 and ~15,500 for FY 2018.
Key Priorities for 2019
GOCOVRI commercialization: The Company will work towards the commercialization of GOCOVRI with the target of doubling of total prescriptions for 2019 over 2018.
Advance the medical literature regarding GOCOVRI in the Parkinson’s disease treatment journey and time dependent mechanisms of disease.
The Company also expects to complete the enrollment for the Phase 3 INROADS study of ADS-5102 (amantadine) for multiple sclerosis walking impairment in H1 2019 and release top-line data in H2 2019.
Adamas will continue to advance ADS-4101 towards registration studies.
Shares are up 9% premarket.
Subscribe for full text news in your inbox